The Treatment of High Intensity Transcranial Current Stimulation for Alzheimer's Disease

Launched by ANHUI PROVINCIAL HOSPITAL · Apr 18, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called transcranial alternating current stimulation (tACS) for people with Alzheimer’s disease and mild cognitive impairment. Alzheimer’s is a type of dementia that affects memory and thinking skills, and current treatments can be costly and may have side effects. The goal of this study is to see if tACS can improve cognitive function (how well a person thinks and remembers) in patients with Alzheimer's.

To participate in the trial, individuals must be diagnosed with Alzheimer's disease and meet certain criteria, such as having a specific level of cognitive impairment and a positive brain scan indicating amyloid buildup, which is associated with Alzheimer's. Participants will need to be able to undergo tests and evaluations, and they should not have other serious mental health issues or other types of dementia. The trial is not yet recruiting, but once it starts, participants can expect to undergo various assessments and receive either the tACS treatment or a placebo (a treatment that doesn't have an active ingredient) to compare effects. This study aims to provide valuable insights into new ways to help those with Alzheimer’s disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Meet the diagnostic criteria of National Institute on Aging and Alzheimer's Association (NIA-AA) 2011 for Alzheimer's disease, Clinical Dementia Rating (CDR) score is greater than or equal to 0.5 and less than or equal to 1, and amyloid PET imaging is positive.
• • 2. Have the ability to cooperate with neuropsychological testing, EEG measurement, and MRI examination;
• • 3. Have willingness to undergo cognitive psychological evaluation;
• • 4. Do not have cognitive impairment due to other degenerative diseases or viral and immune encephalitis;
• • 5. The length of schooling is at least 3 years.
• Exclusion Criteria:
• • 1. Do not suffer from severe depression, anxiety and other mental illness;
• • 2. Do not suffer from major diseases such as tumors, heart and lung diseases, nervous system diseases, etc.
• • 3. Do not have been diagnosed with other dementia such as Parkinson's disease dementia (PDD), frontotemporal dementia (FTD), lewy body dementia (DLB), and normal cranial pressure hydrocephalus (NPH).